Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC), according to a review published online Jan. 21 in the ...

vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic review and meta analysis. Baseline characteristics of patients with combined ...

Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials. 3-year, 4-year and 5-year OS rate of patients who receive ...

This study investigated the role of PLECTIN, a cytoskeletal crosslinker protein, in liver cancer formation and progression. Using the liver-specific Plectin knockout mouse model, the authors ...

By contrast, in patients with hepatocellular carcinoma (HCC) the prediction of prognosis is more complex. There is no worldwide consensus on the use of any HCC staging system. Classifications that ...

1Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. 2Department of Translational Medicine (DIMET), University of Piemonte ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.